surpass cvot tirzepatide results Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the Clinical Trial Program | Cardiovascular Diabetology An Observational Study of Cardiovascular

At six months, patients treated with tirzepatide experienced greater average weight loss (-11.15% vs -8.83%)

You may also have your prescription sent to your local pharmacy for pickup

Clinical Diabetes: A Publication of the American Diabetes Association, 41 (3), 467473

When to Speak to Your Prescriber If you are on a weight loss injection and have genuinely stalled for a sustained period, your prescriber can review whether you are due a dose increase, since plateaus often resolve at the next step up

February 23, 2026: New Weight Loss Drug Fails to Outperform Zepbound in Clinical Trial Zepbound was not outperformed in a clinical trial of a competitors new GLP-1 weight loss drug formulation

Each pre-filled injection is administered once in a week